UK Regulator Clears CuraTeQ’s Filgrastim Biosimilar Zefylti

Aurobindo Pharma Ltd. on Tuesday said its wholly-owned step-down unit CuraTeQ Biologics s.r.o. has received approval from the UK’s Medicines and Healthcare products Regulatory Agency to market Zefylti, a biosimilar of filgrastim.

In February, CuraTeQ Biologics had secured authorisation from the European Commission to sell the drug across the European Union, the company said in an exchange filing.

Zefylti is used to treat neutropenia and to mobilise peripheral progenitor cells. This is CuraTeQ’s second biosimilar to receive MHRA approval after Bevqolva, which was cleared in December.